株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界の遺伝子組換えタンパク質医薬品市場

Global Markets for Bioengineered Protein Drugs

発行 BCC Research 商品コード 311228
出版日 ページ情報 英文 146 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.16円で換算しております。
Back to Top
世界の遺伝子組換えタンパク質医薬品市場 Global Markets for Bioengineered Protein Drugs
出版日: 2016年12月29日 ページ情報: 英文 146 Pages
担当者のコメント
BCC Research社のレポートは、Reuter、Wall Street Journal、Fortuneなどで引用されることも多く、それぞれの業界の識者の意見として重きを置かれています。同社レポートを複数冊ご購入の場合年間パッケージのご契約がお得です。詳細は右の担当者のおすすめ商品よりご覧下さい。
概要

世界における遺伝子組換えタンパク質医薬品の市場規模は、2016年の1725億米ドルから2021年までに2284億米ドルへ達すると予測され、2016年から2021年のCAGR (年間複合成長率) は5.8%が見込まれています。

当レポートでは、世界の遺伝子組換えタンパク質医薬品の市場について調査し、遺伝子組換えタンパク質医薬品の概要、発展の経緯、製造および投与技術、新たな開発の動向、薬剤の分類・適応症・地域別の市場概要および市場収益の推移と予測、産業構造と主要事業者の市場シェア、特許情報、主要事業者のプロファイルなどを詳細に渡ってまとめています。

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 概要

  • タンパク質の合成
  • 遺伝子組換えタンパク質医薬品
  • 製造技術
  • 遺伝子組換えタンパク質医薬品の投与技術
  • 分子分類

第4章 法規制的側面

  • モノクローナル抗体
  • サイトカイン
  • ワクチン
  • ペプチドホルモン
  • 治療用酵素
  • 血液製剤
  • ペプチド抗体
  • リコール
  • 安全警告

第5章 新たな開発

  • モノクローナル抗体
  • ワクチン
  • サイトカイン
  • ペプチドホルモン
  • ペプチド抗体
  • 治療用酵素
  • 血液製剤
  • ペプチド抗体
  • M&A

第6章 市場分析:種類別

  • 種類別市場
    • 市場概要
    • 市場収益
    • 市場シェア
    • ペプチドホルモン
    • ワクチン
    • 治療用酵素
    • モノクローナル抗体
    • サイトカイン
    • 血液製剤・ペプチド抗体

第7章 産業構造

  • ペプチドホルモン
  • ワクチン
  • 治療用酵素
  • モノクローナル抗体
  • サイトカイン
  • 血液因子
  • ペプチド抗体
  • 産業構造

第8章 市場:疾患別

  • 疾患別市場
    • 市場概要
    • 市場収益
    • 市場シェア
    • 糖尿病
    • 血液障害・皮膚疾患
    • 成長ホルモン障害・酵素障害・受胎障害
    • その他

第9章 特許分析

  • 年度別
  • 種類別
  • 企業別
  • 国別
  • 出願者別

第10章 現在の状況

  • 遺伝子組換えタンパク質医薬品への影響因子

第11章 企業プロファイル

  • ABBVIE INC.
  • ACTAVIS INC.
  • ALEXION PHARMACEUTICALS
  • ALLERGAN PLC.
  • AMGEN INC
  • APOTEX INC.
  • BAXALTA INC
  • BAYER HEALTHCARE PHARMACEUTICALS
  • BIOMARIN PHARMACEUTICAL INC.
  • BIOGEN IDEC
  • BIOTEST PHARMACEUTICALS CORPORATION
  • BRISTOL-MYERS SQUIBB
  • CSL LIMITED
  • ELI LILLY
  • FRESENIUS KABI USA
  • GLAXOSMITHKLINE
  • GRIFOLS USA LLC.
  • HOFFMAN-LA ROCHE
  • HOSPIRA INC.
  • JOHNSON & JOHNSON
  • MEDIMMUNE LLC
  • MERCK & CO, INC
  • MYLAN INC.
  • NOVARTIS AG
  • NOVO NORDISK AG
  • OCTAPHARMA AG
  • PFIZER INC
  • SANOFI INC
  • SEATTLE GENETICS INC.
  • SPECTRUM PHARMACEUTICALS INC.
  • TAKEDA PHARMACEUTICAL U.S.A., INC
  • UCB COMPANY

第12章 付録I:略語

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: BIO009G

The global market for bioengineered protein drugs is expected to reach $228.4 billion by 2021 from $172.5 billion in 2016, rising at a compound annual growth rate (CAGR) of 5.8% from 2016 through 2021.

Report Includes

  • An overview of the global market for bioengineered protein drugs.
  • Analyses of global market trends, with data from 2014 and 2015, estimates for 2016, and projections of compound annual growth rates (CAGRs) through 2021.
  • Coverage of proteins that are used for therapeutic purposes, including an analysis of protein-based drugs in clinical trials.
  • A look at current technologies underlying the market as well as the effects new technologies will have on the market.
  • An analysis of the patent landscape in this field and the companies with the greatest breadth in their IP portfolios.
  • Profiles major companies involved in the production and modification of protein drugs.

Report Scope

Bioengineered protein drugs are drugs that help treat chronic diseases like diabetes, asthma, cancer, various blood disorders, fertility disorders, immunological disorders and hormonal disorders. This report focuses on the global bioengineered protein drug market and its products, and provides an updated review of its applications in various arenas of biomedical research.

The scope of the study is global. BCC Research analyzes each market and its application, regulatory environment, technologies involved, new products and advancements, market projections and market shares. The technological issues include all the latest trends, pipeline products and developments.

The bioengineered protein drugs that are covered in this report are monoclonal antibodies, cytokines, peptide antibiotics, vaccines, therapeutic enzymes, blood factors, and peptide hormones. These products are all bioengineered and produced by recombinant DNA technology.

The geographical regions covered in the report are North America, Europe, and emerging markets. The emerging market segment covers countries including India, China, Japan, Korea, Taiwan, Africa, Australia, New Zealand, and Canada among others.

Also included in the report are relevant patent analysis and comprehensive profiles of companies that lead to the bioengineered protein drugs industry. Some of the major players of the market include Eli Lilly and Co., AbbVie Inc., F. Hoffmann-La Roche Ltd., Sanofi S.A., Novo Nordisk AG, Novartis AG, Merck & Co., Merck KGaA and Amgen Inc., among others.

Analyst Credentials

The study has been carried out by a team of professionals in the biotechnology industry. The project manager is Shalini S. Dewan, who holds a master's degree in pharmaceutical chemistry and has over 14 years of industry experience. She was awarded a Gold Medal by the Prime Minister of India for her work and has worked with top companies in India and in the U.S.

Table of Contents

CHAPTER 1 INTRODUCTION

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THIS STUDY
  • CONTRIBUTIONS OF THE STUDY AND FOR WHOM
  • SCOPE OF THE STUDY
  • METHODOLOGY
  • INFORMATION SOURCES
  • ANALYST'S CREDENTIALS
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH WEBSITE
  • DISCLAIMER

CHAPTER 2 EXECUTIVE SUMMARY

  • SUMMARY TABLE GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS, BY REGION, THROUGH 2021 ($ MILLIONS)
  • SUMMARY FIGURE GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS, BY REGION, 2014-2021 ($ MILLIONS)

CHAPTER 3 OVERVIEW

  • BIOSYNTHESIS OF PROTEINS
    • TRANSCRIPTION
    • TRANSLATION
    • POST-TRANSLATIONAL MODIFICATION
  • BIOENGINEERED PROTEIN DRUGS
  • TABLE 1 BIOENGINEERED PROTEIN DRUGS VS. CHEMICALLY SYNTHESIZED DRUGS
    • HISTORY OF BIOENGINEERED PROTEIN DRUGS
    • TABLE 2 EVOLUTION OF BIOENGINEERED PROTEIN DRUGS
    • ADVANTAGES OF BIOENGINEERED PROTEIN DRUGS
  • MANUFACTURING TECHNOLOGY
    • FRACTIONATION/COHN'S METHOD
    • TABLE 3 PROTEIN DRUGS MADE BY FRACTIONATION
    • MICROBIAL/FERMENTATION PROCESS
    • TABLE 4 THERAPETIC DRUGS PRODUCED BY MICROBIAL FERMENTATION
    • GENETIC ENGINEERING
    • GENETICALLY MODIFIED ORGANISMS
    • PHARMING
    • TABLE 5 PROTEIN DRUGS PRODUCED BY TRANSGENIC ANIMALS, PLANTS AND MICROORGANISMS
    • MAMMALIAN CELL CULTURE
    • TABLE 6 PROTEIN DRUGS MADE BY MAMMALIAN CELL CULTURE
  • ADMINISTRATION TECHNOLOGIES OF BIOENGINEERED PROTEIN DRUGS
    • USE OF DRUG DELIVERY SYSTEMS IN CURRENT MEDICAL APPROACHES
    • TRADITIONAL METHODS OF DRUG DELIVERY
      • Oral
      • Topical
      • Trans mucosal
      • Inhalation
      • Parenteral
      • TABLE 7 ROUTES OF DRUG DELIVERY
      • Limitations Encountered by Traditional Drug Delivery
  • MOLECULAR CLASSIFICATION
    • MONOCLONAL ANTIBODIES
    • CYTOKINES
      • Interferons
      • Interleukins
      • Colony Stimulating Factors
    • PEPTIDE HORMONES
      • Follicle Stimulating Hormone and Luteinizing Hormone
      • Growth Hormones
      • Erythropoietin
      • Insulin
    • BLOOD PRODUCTS
      • Alpha 1-Protease Inhibitor
      • Anti-Hemophilic Factor
      • Anti-Thrombin
      • C1-Esterase Inhibitor
      • Coagulation Factors
      • Immunoglobulins
      • Protein C
      • Thrombin
    • PEPTIDE ANTIBIOTICS
    • VACCINES
    • THERAPEUTIC ENZYMES

CHAPTER 4 REGULATORY ASPECTS

  • MONOCLONAL ANTIBODIES
  • TABLE 8 NEW APPROVALS OF MONOCLONAL ANTIBODIES (FROM 2014-MAY 2016)
  • CYTOKINES
  • TABLE 9 NEW APPROVALS OF CYTOKINES (FROM 2014-2015)*
  • VACCINES
  • TABLE 10 NEW APPROVALS IN VACCINES (FROM 2014-MAY 2016)
  • PEPTIDE HORMONES
  • TABLE 11 NEW APPROVALS IN PEPTIDE HORMONES (FROM 2014-2015)*
  • THERAPUETIC ENZYMES
  • TABLE 12 NEW APPROVALS IN THERAPEUTIC ENZYMES (FROM 2014-2015)*
  • BLOOD PRODUCTS
  • TABLE 13 NEW APPROVALS IN BLOOD PRODUCTS (FROM 2014-MAY 2016)
  • PEPTIDE ANTIBIOTICS
  • TABLE 14 NEW APPROVALS IN PEPTIDE ANTIBIOTICS (FROM 2014-2015)*
  • RECALLS
  • TABLE 15 RECALLS (FROM 2014-2015)*
  • SAFETY ALERTS
  • TABLE 16 SAFETY ALERTS (FROM 2014-2015)*

CHAPTER 5 NEW DEVELOPMENTS

  • MONOCLONAL ANTIBODIES
  • TABLE 17 PIPELINE PRODUCTS OF MONOCLONAL ANTIBODIES
  • VACCINES
  • TABLE 18 PIPELINE PRODUCTS OF VACCINES
  • CYTOKINES
  • TABLE 19 PIPELINE PRODUCTS OF CYTOKINES
  • PEPTIDE HORMONES
  • TABLE 20 PIPELINE PRODUCTS OF PEPTIDE HORMONES
  • PEPTIDE ANTIBIOTICS
  • TABLE 21 PIEPLINES PRODUCTS OF PEPTIDE ANTIBIOTICS
  • THERAPUETIC ENZYMES
  • TABLE 22 PIPELINE PRODUCTS OF THERAPUETIC ENZYMES
  • BLOOD PRODUCTS
  • TABLE 23 PIPELINE PRODUCTS OF BLOOD PRODUCTS
  • MERGERS AND ACQUISITIONS
  • TABLE 24 MERGERS AND ACQUISITIONS OF TOP PHARMACEUTICAL COMPANIES

CHAPTER 6 MARKET ANALYSIS BY TYPE

  • MARKET BY TYPE
    • MARKET OVERVIEW
    • MARKET REVENUE
    • TABLE 25 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS, BY TYPE, THROUGH 2021 ($ MILLIONS)
    • FIGURE 1 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS, BY TYPE, 2014-2021 ($ MILLIONS)
    • MARKET SHARE
    • TABLE 26 GLOBAL MARKET SHARE FOR BIOENGINEERED PROTEIN DRUGS, BY TYPE, 2015 (%)
    • FIGURE 2 GLOBAL MARKET SHARE FOR BIOENGINEERED PROTEIN DRUGS, BY TYPE, 2015 (%)
    • PEPTIDE HORMONES
      • Market Overview
      • Market Revenue
      • TABLE 27 GLOBAL MARKET FOR PEPTIDE HORMONES, BY REGION, THROUGH 2021 ($ MILLIONS)
      • FIGURE 3 GLOBAL MARKET FOR PEPTIDE HORMONES, BY REGION, 2014-2021 ($ MILLIONS)
    • VACCINES
      • Market Overview
      • Market Revenue
      • TABLE 28 GLOBAL MARKET FOR VACCINES, BY REGION, THROUGH
      • FIGURE 4 GLOBAL MARKET FOR VACCINES, BY REGION, 2014-2021 ($ MILLIONS)
    • THERAPEUTIC ENZYMES
      • Market Overview
      • Market Revenue
      • TABLE 29 GLOBAL MARKET FOR THERAPEUTIC ENZYMES, BY REGION, THROUGH 2021 ($ MILLIONS)
      • FIGURE 5 GLOBAL MARKET FOR THERAPEUTIC ENZYMES, BY REGION, 2014-2021 ($ MILLIONS)
    • MONOCLONAL ANTIBODIES
      • Market Overview
      • Market Revenue
      • TABLE 30 GLOBAL MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, THROUGH 2021 ($ MILLIONS)
      • FIGURE 6 GLOBAL MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2014-2021 ($ MILLIONS)
    • CYTOKINES
      • Market Overview
      • Market Revenue
      • TABLE 31 GLOBAL MARKET FOR CYTOKINES, BY REGION, THROUGH 2021 ($ MILLIONS)
      • FIGURE 7 GLOBAL MARKET FOR CYTOKINES, BY REGION, 2014-2021 ($ MILLIONS)
    • BLOOD PRODUCTS AND PEPTIDE ANTIBIOTICS
      • Market Overview
      • Market Revenue
      • TABLE 32 GLOBAL MARKET FOR BLOOD FACTORS AND PEPTIDE ANTIBIOTICS, BY REGION, THROUGH 2021 ($ MILLIONS)
      • FIGURE 8 GLOBAL MARKET FOR BLOOD FACTORS AND PEPTIDE ANTIBIOTICS, BY REGION, 2014-2021 ($ MILLIONS)

CHAPTER 7 INDUSTRY STRUCTURE

  • PEPTIDE HORMONES
    • MARKET LEADERS
    • TABLE 33 LEADING MANUFACTURERS/SUPPLIERS OF PEPTIDE HORMONES, 2015
    • MARKET SHARE
    • TABLE 34 GLOBAL MARKET SHARE OF MANUFACTURERS AND SUPPLIERS FOR BIOENGINEERED PEPTIDE HORMONES, 2015 (%)
    • FIGURE 9 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR BIOENGINEERED PEPTIDE HORMONES, 2015 (%)
  • VACCINES
    • MARKET LEADERS
    • TABLE 35 LEADING MANUFACTURERS/SUPPLIERS OF VACCINES, 2015
    • MARKET SHARE
    • TABLE 36 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR VACCINES, 2015 (%)
    • FIGURE 10 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR VACCINES, 2015 (%)
  • THERAPEUTIC ENZYMES
    • MARKET LEADERS
    • TABLE 37 LEADING MANUFACTURERS/SUPPLIERS OF THERAPEUTIC ENZYMES, 2015
    • MARKET SHARE
    • TABLE 38 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR THERAPEUTIC ENZYMES, 2015 (%)
    • FIGURE 11 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR THERAPEUTIC ENZYMES, 2015 (%)
  • MONOCLONAL ANTIBODIES
    • MARKET LEADERS
    • TABLE 39 LEADING MANUFACTURERS/SUPPLIERS OF MONOCLONAL ANTIBODIES, 2015
    • MARKET SHARE
    • TABLE 40 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR MONOCLONAL ANTIBODIES, 2015 (%)
    • FIGURE 12 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR MONOCLONAL ANTIBODIES, 2015 (%)
  • CYTOKINES
    • MARKET LEADERS
    • TABLE 41 LEADING MANUFACTURERS/SUPPLIERS OF CYTOKINES, 2015
    • MARKET SHARE
    • TABLE 42 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR CYTOKINE, 2015 (%)
    • FIGURE 13 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR CYTOKINE, 2015 (%)
  • BLOOD FACTORS
    • MARKET LEADERS
    • TABLE 43 LEADING MANUFACTURERS/SUPPLIERS OF RECOMBINANT BLOOD PRODUCTS, 2015
    • MARKET SHARE
    • TABLE 44 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR RECOMBINANT BLOOD PRODUCTS, 2015 (%)
    • FIGURE 14 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR RECOMBINANT BLOOD PRODUCTS, 2015 (%)
  • PEPTIDE ANTIBIOTICS
    • MARKET LEADERS
    • TABLE 45 LEADING MANUFACTURERS/SUPPLIERS OF PEPTIDE ANTIBIOTICS, 2015
    • MARKET SHARE
    • TABLE 46 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR PEPTIDE ANTIBIOTICS, 2015 (%)
    • FIGURE 15 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR PEPTIDE ANTIBIOTICS, 2015 (%)

CHAPTER 8 MARKET BY DISEASE

  • MARKET BY DISEASE
    • MARKET OVERVIEW
    • MARKET REVENUE
    • TABLE 47 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS, BY DISEASE, THROUGH 2021 ($ MILLIONS)
    • FIGURE 16 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS, BY DISEASE, 2014-2021 ($ MILLIONS)
    • MARKET SHARE
    • TABLE 48 GLOBAL MARKET SHARE FOR BIOENGINEERED PROTEIN DRUGS, BY DISEASE, 2015
    • FIGURE 17 GLOBAL MARKET SHARE FOR BIOENGINEERED PROTEIN DRUGS, BY DISEASE, 2015 (%)
    • DIABETES
      • Type 1 Diabetes
      • Type 2 Diabetes
      • Gestational Diabetes
      • Market Overview
      • Market Revenue
      • TABLE 49 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS FOR DIABETES, BY REGION, THROUGH 2021 ($ MILLIONS)
      • FIGURE 18 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS FOR DIABETES, BY REGION, 2014-2021 ($ MILLIONS)
    • CANCER
    • TABLE 50 VARIOUS CANCER TYPES DEPENDING ON THE TISSUE OF ORIGIN
    • TABLE 51 CATEGORIES OF CANCER
      • Market Overview
      • Market Revenue
      • TABLE 52 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS FOR CANCER, BY REGION, THROUGH 2021 ($ MILLIONS)
      • FIGURE 19 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS FOR CANCER, BY REGION, 2014-2021 ($ MILLIONS)
    • BLOOD DISORDERS AND SKIN DISEASES
      • Blood Disorders
        • Bleeding Disorders
        • Anemia
        • Leukemia
        • Multiple Myeloma
      • Skin Diseases
        • Skin and Skin structure Infections (SSSI)
          • Complicated Skin and Skin structure Infection (cSSSI)
          • Uncomplicated Skin and Skin structure Infection (uSSSI)
        • Clostridium difficile (C. difficile)
      • Market Overview
      • Market Revenue
      • TABLE 53 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS FOR BLOOD DISORDERS AND SKIN DISEASES, BY REGION, THROUGH 2021 ($ MILLIONS)
      • FIGURE 20 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS FOR BLOOD DISORDERS AND SKIN DISEASES, BY REGION, 2014-2021 ($ MILLIONS)
    • GROWTH HORMONE DISORDER, ENZYME DISORDER AND FERTILITY DISORDER
      • Market Overview
      • Market Revenue
      • TABLE 54 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS FOR GROWTH HORMONE, ENZYME AND FERTILITY DISORDERS, BY REGION, THROUGH 2021 ($ MILLIONS)
      • FIGURE 21 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS FOR GROWTH HORMONE, ENZYME AND FERTILITY DISORDERS, BY REGION, 2014-2021 ($ MILLIONS)
    • OTHERS
      • Multiple Sclerosis
      • Hepatitis
      • Crohn's Disease
      • Influenza
      • Pneumonia
      • Cystic Fibrosis
      • Asthma
      • Meningitis
      • Rheumatoid Arthritis
      • Market Overview
      • Market Revenue
      • TABLE 55 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS FOR OTHER DISEASES, BY REGION, THROUGH 2021 ($ MILLIONS)
      • FIGURE 22 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS FOR OTHER DISEASES, BY REGION, 2014-2021 ($ MILLIONS)

CHAPTER 9 PATENT ANALYSIS

  • PATENTS BY YEAR
  • TABLE 56 NUMBER OF PATENTS GRANTED IN MANUFACTURING OF PROTEIN DRUGS, BY YEAR, 2014-JUNE 2016
  • FIGURE 23 NUMBER OF PATENTS GRANTED IN MANUFACTURING OF PROTEIN DRUGS, BY YEAR, 2014-JUNE 2016
  • PATENTS BY TYPE
  • TABLE 57 NUMBER OF PATENTS GRANTED IN MANUFACTURING OF PROTEIN DRUGS, BY TYPE, 2014-JUNE 2016
  • FIGURE 24 NUMBER OF PATENTS GRANTED IN MANUFACTURING OF PROTEIN DRUGS, BY TYPE, 2014-JUNE 2016
  • PATENTS BY COMPANY
  • TABLE 58 NUMBER OF PATENTS GRANTED IN MANUFACTURING OF PROTEIN DRUGS, BY COMPANY, 2014-JUNE 2016
  • PATENTS BY COUNTRY
  • TABLE 59 NUMBER OF PATENTS GRANTED IN MANUFACTURING OF PROTEIN DRUGS, BY COUNTRY,* 2014-JUNE 2016
  • TABLE 60 PATENT SHARES FOR MANUFACTURING OF PROTEIN DRUGS, BY COUNTRY, 2014-JUNE 2016 (NO./%)
  • PATENTS BY ASSIGNEE
  • TABLE 61 NUMBER OF PATENTS, BY ASSIGNEE, 2014-JUNE 2016
  • FIGURE 25 NUMBER OF PATENTS, BY ASSIGNEE, 2014-JUNE 2016

CHAPTER 10 CURRENT SITUATION 137

  • FACTORS AFFECTING BIOENGINEERED PROTEIN DRUGS
    • INCREASING PREVALENCE OF CHRONIC DISEASES
    • GROWING AGING POPULATION
    • LIFESTYLE CHANGES
    • AWARENESS AND EDUCATION
    • ADVANCEMENTS IN MANUFACTURING TECHNOLOGIES
    • PRICE CONTROLS
    • REGULATORY PRESSURES
    • LICENSING AGREEMENTS
    • MERGERS AND ACQUISITIONS
    • ENTRY OF FOLLOW-ON-BIOLOGICS/BIOSIMILARS

CHAPTER 11 COMPANY PROFILES

  • ABBVIE INC.
  • ACTAVIS INC.
  • ALEXION PHARMACEUTICALS
  • ALLERGAN PLC.
  • AMGEN INC
  • APOTEX INC.
  • BAXALTA INC
  • BAYER HEALTHCARE PHARMACEUTICALS
  • BIOMARIN PHARMACEUTICAL INC.
  • BIOGEN IDEC
  • BIOTEST PHARMACEUTICALS CORPORATION
  • BRISTOL-MYERS SQUIBB
  • CSL LIMITED
  • ELI LILLY
  • FRESENIUS KABI USA
  • GLAXOSMITHKLINE
  • GRIFOLS USA LLC.
  • HOFFMAN-LA ROCHE
  • HOSPIRA INC.
  • JOHNSON & JOHNSON
  • MEDIMMUNE LLC
  • MERCK & CO, INC
  • MYLAN INC.
  • NOVARTIS AG
  • NOVO NORDISK AG
  • OCTAPHARMA AG
  • PFIZER INC
  • SANOFI INC
  • SEATTLE GENETICS INC.
  • SPECTRUM PHARMACEUTICALS INC.
  • TAKEDA PHARMACEUTICAL U.S.A., INC
  • UCB COMPANY

CHAPTER 12 APPENDIX I-ABBREVIATIONS

LIST OF TABLES

  • SUMMARY TABLE GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS, BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 1 BIOENGINEERED PROTEIN DRUGS VS. CHEMICALLY SYNTHESIZED DRUGS
  • TABLE 2 EVOLUTION OF BIOENGINEERED PROTEIN DRUGS
  • TABLE 3 PROTEIN DRUGS MADE BY FRACTIONATION
  • TABLE 4 THERAPETIC DRUGS PRODUCED BY MICROBIAL FERMENTATION
  • TABLE 5 PROTEIN DRUGS PRODUCED BY TRANSGENIC ANIMALS, PLANTS AND MICROORGANISMS
  • TABLE 6 PROTEIN DRUGS MADE BY MAMMALIAN CELL CULTURE
  • TABLE 7 ROUTES OF DRUG DELIVERY
  • TABLE 8 NEW APPROVALS OF MONOCLONAL ANTIBODIES (FROM 2014-MAY 2016)
  • TABLE 9 NEW APPROVALS OF CYTOKINES (FROM 2014-2015)*
  • TABLE 10 NEW APPROVALS IN VACCINES (FROM 2014-MAY 2016)
  • TABLE 11 NEW APPROVALS IN PEPTIDE HORMONES (FROM 2014-2015)*
  • TABLE 12 NEW APPROVALS IN THERAPEUTIC ENZYMES (FROM 2014-2015)*
  • TABLE 13 NEW APPROVALS IN BLOOD PRODUCTS (FROM 2014-MAY 2016)
  • TABLE 14 NEW APPROVALS IN PEPTIDE ANTIBIOTICS (FROM 2014-2015)*
  • TABLE 15 RECALLS (FROM 2014-2015)*
  • TABLE 16 SAFETY ALERTS (FROM 2014-2015)*
  • TABLE 17 PIPELINE PRODUCTS OF MONOCLONAL ANTIBODIES
  • TABLE 18 PIPELINE PRODUCTS OF VACCINES
  • TABLE 19 PIPELINE PRODUCTS OF CYTOKINES
  • TABLE 20 PIPELINE PRODUCTS OF PEPTIDE HORMONES
  • TABLE 21 PIEPLINES PRODUCTS OF PEPTIDE ANTIBIOTICS
  • TABLE 22 PIPELINE PRODUCTS OF THERAPUETIC ENZYMES
  • TABLE 23 PIPELINE PRODUCTS OF BLOOD PRODUCTS
  • TABLE 24 MERGERS AND ACQUISITIONS OF TOP PHARMACEUTICAL COMPANIES
  • TABLE 25 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS, BY TYPE, THROUGH 2021 ($ MILLIONS)
  • TABLE 26 GLOBAL MARKET SHARE FOR BIOENGINEERED PROTEIN DRUGS, BY TYPE, 2015 (%)
  • TABLE 27 GLOBAL MARKET FOR PEPTIDE HORMONES, BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 28 GLOBAL MARKET FOR VACCINES, BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 29 GLOBAL MARKET FOR THERAPEUTIC ENZYMES, BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 30 GLOBAL MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 31 GLOBAL MARKET FOR CYTOKINES, BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 32 GLOBAL MARKET FOR BLOOD FACTORS AND PEPTIDE ANTIBIOTICS, BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 33 LEADING MANUFACTURERS/SUPPLIERS OF PEPTIDE HORMONES, 2015
  • TABLE 34 GLOBAL MARKET SHARE OF MANUFACTURERS AND SUPPLIERS FOR BIOENGINEERED PEPTIDE HORMONES, 2015 (%)
  • TABLE 35 LEADING MANUFACTURERS/SUPPLIERS OF VACCINES, 2015
  • TABLE 36 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR VACCINES, 2015 (%)
  • TABLE 37 LEADING MANUFACTURERS/SUPPLIERS OF THERAPEUTIC ENZYMES, 2015
  • TABLE 38 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR THERAPEUTIC ENZYMES, 2015 (%)
  • TABLE 39 LEADING MANUFACTURERS/SUPPLIERS OF MONOCLONAL ANTIBODIES, 2015
  • TABLE 40 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR MONOCLONAL ANTIBODIES, 2015 (%)
  • TABLE 41 LEADING MANUFACTURERS/SUPPLIERS OF CYTOKINES, 2015
  • TABLE 42 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR CYTOKINE, 2015 (%)
  • TABLE 43 LEADING MANUFACTURERS/SUPPLIERS OF RECOMBINANT BLOOD PRODUCTS, 2015
  • TABLE 44 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR RECOMBINANT BLOOD PRODUCTS, 2015 (%)
  • TABLE 45 LEADING MANUFACTURERS/SUPPLIERS OF PEPTIDE ANTIBIOTICS, 2015
  • TABLE 46 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR PEPTIDE ANTIBIOTICS, 2015 (%)
  • TABLE 47 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS, BY DISEASE, THROUGH 2021 ($ MILLIONS)
  • TABLE 48 GLOBAL MARKET SHARE FOR BIOENGINEERED PROTEIN DRUGS, BY DISEASE, 2015
  • TABLE 49 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS FOR DIABETES, BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 50 VARIOUS CANCER TYPES DEPENDING ON THE TISSUE OF ORIGIN
  • TABLE 51 CATEGORIES OF CANCER
  • TABLE 52 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS FOR CANCER, BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 53 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS FOR BLOOD DISORDERS AND SKIN DISEASES, BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 54 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS FOR GROWTH HORMONE, ENZYME AND FERTILITY DISORDERS, BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 55 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS FOR OTHER DISEASES, BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 56 NUMBER OF PATENTS GRANTED IN MANUFACTURING OF PROTEIN DRUGS, BY YEAR, 2014-JUNE 2016
  • TABLE 57 NUMBER OF PATENTS GRANTED IN MANUFACTURING OF PROTEIN DRUGS, BY TYPE, 2014-JUNE 2016
  • TABLE 58 NUMBER OF PATENTS GRANTED IN MANUFACTURING OF PROTEIN DRUGS, BY COMPANY, 2014-JUNE 2016
  • TABLE 59 NUMBER OF PATENTS GRANTED IN MANUFACTURING OF PROTEIN DRUGS, BY COUNTRY,* 2014-JUNE 2016
  • TABLE 60 PATENT SHARES FOR MANUFACTURING OF PROTEIN DRUGS, BY COUNTRY, 2014-JUNE 2016 (NO./%)
  • TABLE 61 NUMBER OF PATENTS, BY ASSIGNEE, 2014-JUNE 2016

LIST OF FIGURES

  • SUMMARY FIGURE GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS, BY REGION, 2014-2021 ($ MILLIONS)
  • FIGURE 1 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS, BY TYPE, 2014-2021 ($ MILLIONS)
  • FIGURE 2 GLOBAL MARKET SHARE FOR BIOENGINEERED PROTEIN DRUGS, BY TYPE, 2015 (%)
  • FIGURE 3 GLOBAL MARKET FOR PEPTIDE HORMONES, BY REGION, 2014-2021 ($ MILLIONS)
  • FIGURE 4 GLOBAL MARKET FOR VACCINES, BY REGION, 2014-2021 ($ MILLIONS)
  • FIGURE 5 GLOBAL MARKET FOR THERAPEUTIC ENZYMES, BY REGION, 2014-2021 ($ MILLIONS)
  • FIGURE 6 GLOBAL MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2014-2021 ($ MILLIONS)
  • FIGURE 7 GLOBAL MARKET FOR CYTOKINES, BY REGION, 2014-2021 ($ MILLIONS)
  • FIGURE 8 GLOBAL MARKET FOR BLOOD FACTORS AND PEPTIDE ANTIBIOTICS, BY REGION, 2014-2021 ($ MILLIONS)
  • FIGURE 9 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR BIOENGINEERED PEPTIDE HORMONES, 2015 (%)
  • FIGURE 10 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR VACCINES, 2015 (%)
  • FIGURE 11 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR THERAPEUTIC ENZYMES, 2015 (%)
  • FIGURE 12 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR MONOCLONAL ANTIBODIES, 2015 (%)
  • FIGURE 13 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR CYTOKINE, 2015 (%)
  • FIGURE 14 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR RECOMBINANT BLOOD PRODUCTS, 2015 (%)
  • FIGURE 15 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR PEPTIDE ANTIBIOTICS, 2015 (%)
  • FIGURE 16 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS, BY DISEASE, 2014-2021 ($ MILLIONS)
  • FIGURE 17 GLOBAL MARKET SHARE FOR BIOENGINEERED PROTEIN DRUGS, BY DISEASE, 2015 (%)
  • FIGURE 18 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS FOR DIABETES, BY REGION, 2014-2021 ($ MILLIONS)
  • FIGURE 19 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS FOR CANCER, BY REGION, 2014-2021 ($ MILLIONS)
  • FIGURE 20 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS FOR BLOOD DISORDERS AND SKIN DISEASES, BY REGION, 2014-2021 ($ MILLIONS)
  • FIGURE 21 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS FOR GROWTH HORMONE, ENZYME AND FERTILITY DISORDERS, BY REGION, 2014-2021 ($ MILLIONS)
  • FIGURE 22 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS FOR OTHER DISEASES, BY REGION, 2014-2021 ($ MILLIONS)
  • FIGURE 23 NUMBER OF PATENTS GRANTED IN MANUFACTURING OF PROTEIN DRUGS, BY YEAR, 2014-JUNE 2016
  • FIGURE 24 NUMBER OF PATENTS GRANTED IN MANUFACTURING OF PROTEIN DRUGS, BY TYPE, 2014-JUNE 2016
  • FIGURE 25 NUMBER OF PATENTS, BY ASSIGNEE, 2014-JUNE 2016
Back to Top